Screening for congenital hypothyroidism: comparison of borderline screening cut-off points and the effect on the number of children treated with levothyroxine.

Shirley Langham, Peter Hindmarsh, Steven Krywawych, Catherine Peters
Author Information
  1. Shirley Langham: Department of Endocrinology, Great Ormond Street Hospital, Hospital for Children, London, UK.
  2. Peter Hindmarsh: Developmental Endocrinology Research Group, Institute of Child Health, University College London, London, UK.
  3. Steven Krywawych: Department of Chemical Pathology, Great Ormond Street Hospital, Hospital for Children, London, UK.
  4. Catherine Peters: Department of Endocrinology, Great Ormond Street Hospital, Hospital for Children, London, UK ; Developmental Endocrinology Research Group, Institute of Child Health, University College London, London, UK.

Abstract

BACKGROUND: The newborn screening programme for congenital hypothyroidism (CH) has led to the prevention of severe developmental delay associated with this condition. In the UK, thyroid-stimulating hormone (TSH) screening cut-off points have changed over time, in some instances prompted by changing methodological platforms. The use of borderline cut-off points varies throughout the country.
OBJECTIVE: To use discordance in cut-off points to assess the performance of the UK Newborn Screening Programme Centre (UKNSPC) definitions.
METHODS: Between January 2006 and December 2007, 223,658 newborn infants were screened by the Great Ormond Street Hospital (GOSH) for CH. All children with positive results and those with blood-spot TSH concentrations >6 mU/l on repeat screening were referred to GOSH. We compared the numbers of children detected and treated for CH using the GOSH cut-off points (>6 mU/l) and those of the national screening programme (>10 mU/l). Children were defined as transient CH if levothyroxine treatment had been discontinued by 3 years.
RESULTS: Of the children screened between January 2006 and December 2007, 167 out of 223,658 fulfilled the GOSH screening criteria; 136 of these required levothyroxine treatment, but 29 (21%) of the children treated would not have been detected by the current UKNSPC guidelines. Transient CH was found in 17/47 (36%) of the treated children detected with a cut-off point >6 mU/l. Raising the cut-off point to >10 mU/l reduced the number of children treated for transient CH to 4/18 (22%).
CONCLUSION: A significant number of children with true and transient CH are missed with a screening cut-off point of >10 mU/l. Our data suggests that a cut-off point of 6 mU/l is appropriate.

Keywords

References

Arch Dis Child. 1985 Jun;60(6):587-92 [PMID: 4015179]
BMC Pediatr. 2010 Feb 15;10:9 [PMID: 20156344]
Arch Dis Child. 2011 Apr;96(4):374-9 [PMID: 21242230]
Clin Endocrinol (Oxf). 2009 Nov;71(5):739-45 [PMID: 19486019]
Pediatrics. 2005 Jan;115(1):e52-7 [PMID: 15629966]
Pediatrics. 2003 Oct;112(4):923-30 [PMID: 14523187]
Arch Dis Child. 1984 Jan;59(1):23-9 [PMID: 6198974]
J Clin Endocrinol Metab. 2008 Jul;93(7):2679-85 [PMID: 18445672]
Curr Opin Pediatr. 1996 Aug;8(4):389-95 [PMID: 8954273]
Arch Dis Child. 2007 Nov;92(11):1048 [PMID: 17846034]
Arch Dis Child. 2010 Mar;95(3):169-73 [PMID: 19679574]
Br Med J (Clin Res Ed). 1984 Nov 3;289(6453):1171-5 [PMID: 6437473]
Br Med J (Clin Res Ed). 1988 May 14;296(6633):1355-8 [PMID: 3134984]

Word Cloud

Similar Articles

Cited By